Tyrosine kinase inhibitor treatment for newly diagnosed chronic myeloid leukemia Journal Article
| Authors: | Radich, J. P.; Mauro, M. J. |
| Article Title: | Tyrosine kinase inhibitor treatment for newly diagnosed chronic myeloid leukemia |
| Abstract: | Chronic myeloid leukemia (CML) is a myeloproliferative disorder that accounts for approximately 10% of new cases of leukemia. The introduction of tyrosine kinase inhibitors has led to a reduction in mortalities. Thus, the estimated prevalence of CML is increasing. The National Comprehensive Cancer Network and the European Leukemia Net guidelines incorporate frequent molecular monitoring of the fusion BCR-ABL transcript to ensure that patients reach and keep treatment milestones. Most patients with CML are diagnosed in the chronic phase, and approximately 10% to 30% of these patients will at some time in their course meet definition criteria of resistance to imatinib. © 2017 Elsevier Inc. |
| Keywords: | treatment response; overall survival; review; interferon; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; hypertension; side effect; cytarabine; cancer staging; imatinib; edema; reverse transcription polymerase chain reaction; bone marrow suppression; bleeding; nausea; thrombocytopenia; vomiting; qt prolongation; dasatinib; chronic myeloid leukemia; mutational analysis; cancer resistance; protein tyrosine kinase inhibitor; hyperglycemia; rash; gastrointestinal toxicity; messenger rna; cardiovascular disease; heart infarction; pancreatitis; patient compliance; pleura effusion; dyslipidemia; headache; bcr abl protein; leukocyte count; point mutation; tyrosine kinase inhibitor; nilotinib; drug substitution; leukemia relapse; pericardial effusion; cerebrovascular accident; fluid retention; muscle cramp; philadelphia 1 chromosome; bcr-abl; molecular response; pulmonary hypertension; musculoskeletal pain; bosutinib; cancer prognosis; medication compliance; long term survival; blood vessel occlusion; peripheral occlusive artery disease; ponatinib; human; priority journal |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 31 |
| Issue: | 4 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-08-01 |
| Start Page: | 577 |
| End Page: | 587 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2017.04.006 |
| PROVIDER: | scopus |
| PUBMED: | 28673389 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 August 2017 -- Source: Scopus |
